Lynda Vuong

2.2k total citations · 1 hit paper
7 papers, 706 citations indexed

About

Lynda Vuong is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Lynda Vuong has authored 7 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Immunology. Recurrent topics in Lynda Vuong's work include Renal cell carcinoma treatment (4 papers), Immune Cell Function and Interaction (3 papers) and Cancer Genomics and Diagnostics (2 papers). Lynda Vuong is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Immune Cell Function and Interaction (3 papers) and Cancer Genomics and Diagnostics (2 papers). Lynda Vuong collaborates with scholars based in United States, Sweden and United Kingdom. Lynda Vuong's co-authors include Martin H. Voss, A. Ari Hakimi, Ritesh R. Kotecha, Alejandro Sánchez, Fengshen Kuo, Timothy A. Chan, Parul Patel, Irina Ostrovnaya, Robert J. Motzer and Albert Reising and has published in prestigious journals such as Cancer Research, The Lancet Oncology and Frontiers in Immunology.

In The Last Decade

Lynda Vuong

7 papers receiving 701 citations

Hit Papers

Tumor Microenvironment Dy... 2019 2026 2021 2023 2019 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lynda Vuong United States 5 426 355 256 189 184 7 706
Takumi Yamaura Japan 13 215 0.5× 200 0.6× 329 1.3× 172 0.9× 156 0.8× 38 603
Linda Mahjoubi France 9 208 0.5× 213 0.6× 369 1.4× 132 0.7× 113 0.6× 12 558
Mika Hoshino Japan 12 173 0.4× 169 0.5× 308 1.2× 158 0.8× 183 1.0× 36 538
Angel Qin United States 12 201 0.5× 178 0.5× 343 1.3× 122 0.6× 94 0.5× 33 561
Mitsuro Fukuhara Japan 12 200 0.5× 110 0.3× 247 1.0× 113 0.6× 108 0.6× 35 460
Giulia Mazzaschi Italy 11 254 0.6× 130 0.4× 444 1.7× 96 0.5× 166 0.9× 54 634
Muhammad Zubair Afzal United States 11 175 0.4× 166 0.5× 383 1.5× 98 0.5× 143 0.8× 31 543
Qiyun Ou China 8 284 0.7× 124 0.3× 366 1.4× 150 0.8× 137 0.7× 24 544
Coraline Duménil France 9 235 0.6× 124 0.3× 427 1.7× 135 0.7× 129 0.7× 20 545
Fenglong Bie China 13 155 0.4× 143 0.4× 211 0.8× 88 0.5× 71 0.4× 32 429

Countries citing papers authored by Lynda Vuong

Since Specialization
Citations

This map shows the geographic impact of Lynda Vuong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynda Vuong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynda Vuong more than expected).

Fields of papers citing papers by Lynda Vuong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynda Vuong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynda Vuong. The network helps show where Lynda Vuong may publish in the future.

Co-authorship network of co-authors of Lynda Vuong

This figure shows the co-authorship network connecting the top 25 collaborators of Lynda Vuong. A scholar is included among the top collaborators of Lynda Vuong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynda Vuong. Lynda Vuong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Roper, James A., Ulf J. Nilsson, Fredrik R. Zetterberg, et al.. (2023). Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1. Frontiers in Immunology. 14. 1250559–1250559. 21 indexed citations
2.
Nixon, Briana G., Fengshen Kuo, Ming Liu, et al.. (2020). IRF8 Governs Tumor-Associated Macrophage Control of T Cell Exhaustion. SSRN Electronic Journal. 4 indexed citations
3.
Vuong, Lynda, Claire Rooney, Brian J. McHugh, et al.. (2019). An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade. Cancer Research. 79(7). 1480–1492. 104 indexed citations
4.
Hakimi, A. Ari, Martin H. Voss, Fengshen Kuo, et al.. (2019). Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery. 9(4). 510–525. 156 indexed citations
5.
Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. 21(2). 283–293. 127 indexed citations
6.
Vuong, Lynda, Ritesh R. Kotecha, Martin H. Voss, & A. Ari Hakimi. (2019). Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discovery. 9(10). 1349–1357. 293 indexed citations breakdown →
7.
Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic Signatures Related to the Obesity Paradox in Patients with Clear Cell Renal Cell Carcinoma. SSRN Electronic Journal. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026